News - Bystolic

Filter

Current filters:

Bystolic

Popular Filters

Forest agrees another license deal for Bystolic

22-07-2013

US drugmaker Forest Laboratories (NYSE:FRX) and Forest Laboratories Holdings have reached a settlement…

Amerigen PharmaceuticalsBystolicCardio-vascularForest LaboratoriesGenericsLicensingNorth AmericaPharmaceutical

Forest Lab's nebivolol and valsartan combo performs well in Ph III hypertension trial

28-06-2013

US drugmaker Forest Laboratories (NYSE:FRX) has announced positive top-line results from an eight-week…

BystolicCardio-vascularDiovanForest LaboratoriesnebivololPharmaceuticalResearchvalsartan

Forest Labs buys Bystolic rights from Janssen for $357 million

03-04-2012

Forest Laboratories, (NYSE: FRX) says it has acquired all US patents and other US and Canadian intellectual…

BystolicCardio-vascularForest LaboratoriesJanssen PharmaceuticaJohnson & JohnsonLicensingNorth AmericaPharmaceuticalSavella

Back to top